Skip to main content

Programmes Vaccines

Oxford Martin Programme on Vaccines

The Oxford Martin Programme on Vaccines was established with Oxford Martin School funding in 2010 and the grant from the School ended in September 2015. Although the programme no longer receives funding from the Oxford Martin School, many of its memberfs are actively involved with the School as Oxford Martin Senior Fellows.

Directors

Adrian Hill, Professor of Human Genetics

Susan Lea, Oxford University Statutory Chair of Microbiology

Andrew Pollard, Professor of Paediatric Infection and Immunity

Christoph Tang, Glaxo Professor of Cellular Pathology

Project Description

The Challenge

The WHO’s World Statistics Report for 2015 shows that more than a quarter of infant deaths are from infectious diseases, and although adult deaths from infectious diseases in the global population are decreasing, they still outrank non-communicable diseases in many poorer nations. The threat of pandemics and mortality from endemic diseases will continue to pose great challenges for vaccine research and development in coming decades.


Ambition

The programme aims to design and develop new vaccines against infectious diseases of global health importance, focusing on six key targets: hepatitis, pandemic influenza, malaria, tuberculosis, HIV/AIDS and meningitis.


Approach

The Oxford Martin Programme on Vaccines brings together Oxford’s diverse range of vaccines research. The collaboration provides a spectrum of expertise unparalleled elsewhere in academia and it enables researchers to move between groups, sharing valuable new perspectives and insights.


Progress

Members of the Oxford Martin Programme on Vaccines were part of the collaboration that developed a new vaccine, Bexsero, to protect against meningitis B. The vaccine is due to become part of the UK’s childhood immunisation scheme in 2015.

Work to stabilise a key component in vaccines against meningococcal disease, enabling them to be stored for months rather than days, has been taken up by Novartis.

Clinical trials are underway into vaccines designed to induce immunity against all types of influenza.

Researchers have developed a new attenuated respiratory virus that could be used as a carrier for vaccines against influenza, dengue and hepatitis C virus.

Novel, needle-free, vaccine delivery routes have been developed by the team and are now at patent application stage.


Potential

the Centre’s contribution to research in this field is already helping to shape policy and management frameworks in many areas of the world, and has the potential to protect vital areas of forest.